Antwerp-based Koios Care, a neurology-focused digital medicine company, has raised €1 million in a seed funding round, led by Evercurious VC with support from Astylab Ventures.
- Founded in 2022 by Gregor Strobbe, Konstantinos Kyritsis, and Dimitris Iakovakis, Koios Care is redefining how neurological conditions are monitored and managed.
- The company develops AI-powered digital health tools that passively collect and analyze data from everyday devices, like smartphones and smartwatches, to generate continuous, clinically meaningful insights into patients’ daily lives.
- These insights empower earlier, more personalized treatment decisions, support value-based care models, and accelerate the development of new therapies through real-world evidence.
- In its most recent study, Koios Care engaged 130 patients across multiple European clinics. Today, its platform is actively used by research institutions, industry partners, and in-hospital pilot programs to optimize treatment strategies and drive innovation in neurological care.
Details of the deal
- The round was led by the Greek early-stage deeptech fund Evercurious VC, with strong participation from Astylab Ventures, imec.istart fund and several private angel investors, coordinated by HeBAN.
"We are impressed by the team's scientific rigor, the clinical validation and the vision to reshape long-term neurodegenerative conditions' care and enable the shift toward personalized, data-driven disease management at scale," claims Alex Vamvakas, partner at Evercurious VC.
- The €1 million seed funding will accelerate Koios Care’s growth by supporting regulatory approval, expanding market commercialization of their "Parkiwatch" platform across EU clinics, and generating ongoing clinical evidence.
"This funding reflects the urgent need for a new standard in care. With our solution, we empower patients to better understand their condition, equip medical teams with unprecedented insights, and provide pharmaceutical companies with a powerful tool to accelerate the development of more effective therapies," co-founder and CTO of Koios Care, Dimitris Iakovakis, stated.
